Pharma BD Deal Intelligence
J&J / Synthes: Partially Achieved (Score: 47/100)
Full analysis, sources & comparables →J&J acquired Synthes for $19.7B for orthopedic implants and trauma devices.
FTC puts conditions on Johnson & Johnsons proposed acquisition of Synthes, requiring J&J to sell its system for surgically treating serious wrist fractures.
Johnson & Johnson completed the acquisition of Synthes, Inc. on June 14, 2012 for a total purchase price of $19.7 billion in cash and stock, creating the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J acquired Synthes for $19.7B for orthopedic implants and trauma devices.
J&J / Synthes: Partially Achieved (Score: 47/100)
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Synthes Inc. (this deal) | 2011 | $19.7B | 77 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2011 deals · Johnson & Johnson deals · Multiple (undisclosed) deals